Summary & Overview
HCPCS J0175: Donanemab-azbt Injection, 2 mg
HCPCS Level II code J0175 denotes the 2 mg unit of donanemab-azbt, a monoclonal antibody administered by injection. As a specialty biologic therapy, donanemab-azbt is billed using this HCPCS Level II code when supplied for patient infusion or injection, typically in outpatient infusion centers or hospital outpatient departments. Nationally, precise coding for high-cost specialty drugs like donanemab-azbt matters for accurate claims processing, benefit design, and cost management across public and private payers.
Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the code’s clinical context and service setting, plus what to expect in payer coverage considerations and common billing practices. The publication summarizes benchmark points, relevant policy developments affecting specialty drug reimbursement, and practical billing and coding considerations tied to HCPCS Level II code J0175. This guide is intended to help billing managers, policy analysts, and revenue cycle staff understand how the code is used and where to look for payer-specific guidance.
Billing Code Overview
HCPCS Level II code J0175 represents the drug injection donanemab-azbt, supplied in a 2 mg unit. This code is used for billing administration of the specified monoclonal antibody formulation.
Service Type: Injection of donanemab-azbt
Typical Site of Service: Infusion center or outpatient clinic
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an older adult with early symptomatic Alzheimer disease evaluated in a neurology clinic for disease-modifying therapy. The patient has undergone cognitive testing, brain MRI to rule out alternative causes, and appropriate counseling regarding risks and benefits. The clinician orders intravenous infusion of J0175 (donanemab-azbt, 2 mg) according to the prescribing information and institutional infusion protocols. The clinical workflow includes pre-infusion assessment (vitals, medication reconciliation, informed consent), baseline laboratory and imaging review, administration of the medication by an infusion nurse in an outpatient infusion center or hospital outpatient department, post-infusion monitoring for infusion reactions or amyloid-related imaging abnormalities (ARIA), and documentation of dose, lot number, and any adverse events. Typical sites of service are an outpatient infusion center, hospital outpatient department, or ambulatory infusion suite. The patient scenario may require coordination with pharmacy for drug preparation, scheduling of follow-up MRI, and periodic cognitive and functional assessments to document response and safety monitoring.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
JW | Drug amount discarded/not administered | Use when part of a single-use vial dose is discarded and the discarded amount must be reported for inventory/tracking or payor requirements. |